Publications by authors named "H Katus"
Article Synopsis
- The study examines the outcomes of cryoballoon-ablation for atrial fibrillation in women, focusing on those with heart failure with preserved ejection fraction (HFpEF) compared to those without.
- Women with HFpEF displayed worse health indicators, including higher left atrial volume, increased left ventricular mass, reduced walking distances, and higher left atrial pressures.
- Results showed that women with HFpEF had more frequent hospitalizations due to AF and did not experience significant improvements in heart failure symptoms or quality of life after the procedure, suggesting they represent a high-risk group.
Background: The EF-hand Ca sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75-94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts.
View Article and Find Full Text PDFArticle Synopsis
- Cardiac macrophages play a crucial role in enhancing electrical conduction through the atrioventricular node (AV) in mice and may influence the effectiveness of antiarrhythmic drugs like flecainide.
- In experiments, mice with modified macrophages showed no significant issues in electrical conduction but had a reduced response to flecainide, reflected in less pronounced changes in heart rhythm intervals.
- Coupling between macrophages and cardiomyocytes improves the drug's effects by increasing the presence of specific proteins (Cx43 and Na1.5) on the cell membrane, leading to greater changes in cell membrane potential and action potential duration.
Background: The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.
Methods: This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020.